Switch theme
Sign up to access all valuation multiples
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
2007
100
LTM Revenue $30.5M
LTM EBITDA -$58.6M
$12.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bionano Genomics has a last 12-month revenue (LTM) of $30.5M and a last 12-month EBITDA of -$58.6M.
In the most recent fiscal year, Bionano Genomics achieved revenue of $30.8M and an EBITDA of -$97.5M.
Bionano Genomics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bionano Genomics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $30.5M | XXX | $30.8M | XXX | XXX | XXX |
| Gross Profit | $5.1M | XXX | $0.4M | XXX | XXX | XXX |
| Gross Margin | 17% | XXX | 1% | XXX | XXX | XXX |
| EBITDA | -$58.6M | XXX | -$97.5M | XXX | XXX | XXX |
| EBITDA Margin | -192% | XXX | -317% | XXX | XXX | XXX |
| EBIT | -$73.3M | XXX | -$76.3M | XXX | XXX | XXX |
| EBIT Margin | -240% | XXX | -248% | XXX | XXX | XXX |
| Net Profit | -$77.1M | XXX | -$112M | XXX | XXX | XXX |
| Net Margin | -253% | XXX | -364% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Bionano Genomics's stock price is $4.
Bionano Genomics has current market cap of $12.3M, and EV of $12.4M.
See Bionano Genomics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12.4M | $12.3M | XXX | XXX | XXX | XXX | $-54.64 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Bionano Genomics has market cap of $12.3M and EV of $12.4M.
Bionano Genomics's trades at 0.4x EV/Revenue multiple, and -0.1x EV/EBITDA.
Equity research analysts estimate Bionano Genomics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bionano Genomics has a P/E ratio of -0.2x.
See valuation multiples for Bionano Genomics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $12.3M | XXX | $12.3M | XXX | XXX | XXX |
| EV (current) | $12.4M | XXX | $12.4M | XXX | XXX | XXX |
| EV/Revenue | 0.4x | XXX | 0.4x | XXX | XXX | XXX |
| EV/EBITDA | -0.2x | XXX | -0.1x | XXX | XXX | XXX |
| EV/EBIT | -0.2x | XXX | -0.2x | XXX | XXX | XXX |
| EV/Gross Profit | 2.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.2x | XXX | -0.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBionano Genomics's last 12 month revenue growth is 5%
Bionano Genomics's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.8M for the same period.
Bionano Genomics's rule of 40 is -586% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bionano Genomics's rule of X is -179% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Bionano Genomics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | -192% | XXX | -317% | XXX | XXX | XXX |
| EBITDA Growth | -81% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -586% | XXX | -312% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -179% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 81% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 249% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bionano Genomics acquired XXX companies to date.
Last acquisition by Bionano Genomics was XXXXXXXX, XXXXX XXXXX XXXXXX . Bionano Genomics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Bionano Genomics founded? | Bionano Genomics was founded in 2007. |
| Where is Bionano Genomics headquartered? | Bionano Genomics is headquartered in United States of America. |
| How many employees does Bionano Genomics have? | As of today, Bionano Genomics has 100 employees. |
| Who is the CEO of Bionano Genomics? | Bionano Genomics's CEO is Dr. R. Erik Holmlin, PhD. |
| Is Bionano Genomics publicy listed? | Yes, Bionano Genomics is a public company listed on NAS. |
| What is the stock symbol of Bionano Genomics? | Bionano Genomics trades under BNGO ticker. |
| When did Bionano Genomics go public? | Bionano Genomics went public in 2018. |
| Who are competitors of Bionano Genomics? | Similar companies to Bionano Genomics include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Bionano Genomics? | Bionano Genomics's current market cap is $12.3M |
| What is the current revenue of Bionano Genomics? | Bionano Genomics's last 12 months revenue is $30.5M. |
| What is the current revenue growth of Bionano Genomics? | Bionano Genomics revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Bionano Genomics? | Current revenue multiple of Bionano Genomics is 0.4x. |
| Is Bionano Genomics profitable? | Yes, Bionano Genomics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Bionano Genomics? | Bionano Genomics's last 12 months EBITDA is -$58.6M. |
| What is Bionano Genomics's EBITDA margin? | Bionano Genomics's last 12 months EBITDA margin is -192%. |
| What is the current EV/EBITDA multiple of Bionano Genomics? | Current EBITDA multiple of Bionano Genomics is -0.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
